Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Legal Officer | April 28, 2020 | April 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date April 28, 2020 · Filed April 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 111,171 |
Ending reported balance
After 2020-04-29 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-04-28 · Exercise / conversion · Acquired 1,220 · Balance 112,391 Row 2 · 2020-04-28 · Sale · Disposed 1,220 · Balance 111,171 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2020-04-29 · Exercise / conversion · Acquired 3,780 · Balance 114,951 Row 4 · 2020-04-29 · Sale · Disposed 3,780 · Balance 111,171 F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2027-07-13 | Direct | 44,413 |
Reported balance
After 2020-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-28 · Exercise / conversion · Disposed 1,220 · Balance 44,413 F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. |
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2027-07-13 | Direct | 40,633 |
Reported balance
After 2020-04-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-29 · Exercise / conversion · Disposed 3,780 · Balance 40,633 F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2020 Filed Apr 30, 2020 18:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 3,780 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-006010 · wf-form4_158828458578863.xml · derivative · entry 6 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,633 Underlying: COMMON STOCK · 3,780 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 18:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,780 | $80.11 | $302,800.30 |
DisclosureSEC source: 0001628280-20-006010 · wf-form4_158828458578863.xml · nonDerivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,171 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 18:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 3,780 | $4.18 | $15,800.40 |
DisclosureSEC source: 0001628280-20-006010 · wf-form4_158828458578863.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 18:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,220 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-006010 · wf-form4_158828458578863.xml · derivative · entry 5 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,413 Underlying: COMMON STOCK · 1,220 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 18:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,220 | $80.02 | $97,627.57 |
DisclosureSEC source: 0001628280-20-006010 · wf-form4_158828458578863.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,171 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 18:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,220 | $4.18 | $5,099.60 |
DisclosureSEC source: 0001628280-20-006010 · wf-form4_158828458578863.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 5,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-005642 · wf-form4_158802105795362.xml · derivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,633 Underlying: COMMON STOCK · 5,000 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. F4 · balance_after: The Form 4 filed by the Reporting Person on August 16, 2019 incorrectly listed 117,560 stock options remaining instead of 67,560. This error was carried through on subsequent filings by the Reporting Person. This Form 4 corrects such error. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,000 | $77.32 | $386,614.50 |
DisclosureSEC source: 0001628280-20-005642 · wf-form4_158802105795362.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,171 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $77.02 to $77.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 16:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 5,000 | $4.18 | $20,900.00 |
DisclosureSEC source: 0001628280-20-005642 · wf-form4_158802105795362.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:36 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 6,148 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-015308 · wf-form4_157739619277683.xml · derivative · entry 6 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,633 Underlying: COMMON STOCK · 6,148 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:36 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,500 | $82.75 | $124,125.00 |
DisclosureSEC source: 0001628280-19-015308 · wf-form4_157739619277683.xml · nonDerivative · entry 5 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,321 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.52 to $83.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:36 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,957 | $81.91 | $160,297.87 |
DisclosureSEC source: 0001628280-19-015308 · wf-form4_157739619277683.xml · nonDerivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,821 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.51 to $82.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:36 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,691 | $80.89 | $217,674.99 |
DisclosureSEC source: 0001628280-19-015308 · wf-form4_157739619277683.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,778 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.50 to $81.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:36 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 6,148 | $4.18 | $25,698.64 |
DisclosureSEC source: 0001628280-19-015308 · wf-form4_157739619277683.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:36 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 14,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-015308 · wf-form4_157739619277683.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,321 F1 · kind: Represents shares of Common Stock that the Reporting Person donated as a gift to a donor advised fund administered by the Deseret Trust Company. Read SEC document |
| December 19, 2019 Filed Dec 19, 2019 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,096 | $79.63 | $724,314.48 |
DisclosureSEC source: 0001628280-19-015244 · wf-form4_157680780034961.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,737 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.50 to $79.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.direct: The Reporting Person does not serve as a trustee or exercise any control over the securities held by the Andrew Wiley 2019 Irrevocable Trust, the Matthew Wiley 2019 Irrevocable Trust, the Isabella Wiley 2019 Irrevocable Trust or the Coleman Wiley 2019 Irrevocable Trust, and thus, the Reporting Person is not deemed to indirectly hold such securities. Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,904 | $79.51 | $310,407.04 |
DisclosureSEC source: 0001628280-19-015244 · wf-form4_157680780034961.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,833 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.50 to $79.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 30,000 | $79.72 | $2,391,600.00 |
DisclosureSEC source: 0001628280-19-015244 · wf-form4_157680780034961.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,737 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.40 to $79.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 6,779 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · derivative · entry 9 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,781 Underlying: COMMON STOCK · 6,779 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,881 | $73.08 | $283,623.48 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 8 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,737 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.72 to $73.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,898 | $72.12 | $209,003.76 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 7 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,618 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.71 to $72.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 6,779 | $4.18 | $28,336.22 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 6 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 5 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| October 10, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| October 10, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| October 10, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 10,000 F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| October 10, 2019 Filed Nov 13, 2019 16:53 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-014124 · wf-form4_157368201395771.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,737 Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 17:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 4,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-011841 · wf-form4_156892704641938.xml · derivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,560 Underlying: COMMON STOCK · 4,000 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 17:04 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 4,000 | $4.18 | $16,720.00 |
DisclosureSEC source: 0001628280-19-011841 · wf-form4_156892704641938.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 30,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010912 · wf-form4_156600200354743.xml · derivative · entry 4 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,560 Underlying: COMMON STOCK · 30,000 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,024 | $101.55 | $103,987.20 |
DisclosureSEC source: 0001628280-19-010912 · wf-form4_156600200354743.xml · nonDerivative · entry 3 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,737 F1 · shares: Some of these shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.51 to $101.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 51,976 | $100.82 | $5,240,220.32 |
DisclosureSEC source: 0001628280-19-010912 · wf-form4_156600200354743.xml · nonDerivative · entry 2 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,761 F1 · shares: Some of these shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.50 to $101.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 30,000 | $4.18 | $125,400.00 |
DisclosureSEC source: 0001628280-19-010912 · wf-form4_156600200354743.xml · nonDerivative · entry 1 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,164 | $98.51 | $114,665.64 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 29 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 0 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.25 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,076 | $97.93 | $203,302.68 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 28 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 1,164 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.24 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,164 | $98.51 | $114,665.64 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 27 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 0 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.25 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,077 | $97.93 | $203,400.61 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 26 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 1,164 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.24 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,164 | $98.51 | $114,665.64 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 25 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 0 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.25 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,077 | $97.93 | $203,400.61 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 24 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 1,164 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.24 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,164 | $98.51 | $114,665.64 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 23 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 0 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.25 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,076 | $97.93 | $203,302.68 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 22 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Isabella Wiley 2019 Irrevocable Trust Disclosed balance after: 1,164 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.24 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 287 | $100.75 | $28,915.25 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 21 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 3,240 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.57 to $101.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,139 | $99.68 | $113,535.52 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 20 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 3,527 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.44 to $100.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,977 | $98.75 | $293,978.75 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 19 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 4,666 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.23 to $99.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,357 | $97.88 | $230,703.16 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 18 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Matthew Wiley 2019 Irrevocable Trust Disclosed balance after: 7,643 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 287 | $100.75 | $28,915.25 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 17 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 3,241 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.57 to $101.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,139 | $99.68 | $113,535.52 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 16 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 3,528 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.44 to $100.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,976 | $98.75 | $293,880.00 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 15 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 4,667 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.23 to $99.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,357 | $97.88 | $230,703.16 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 14 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Coleman Wiley 2019 Irrevocable Trust Disclosed balance after: 7,643 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $98.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:31 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 287 | $100.75 | $28,915.25 |
DisclosureSEC source: 0001628280-19-010910 · wf-form4_156600188688154.xml · nonDerivative · entry 13 Wiley Michael J · CIK 0001753789 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Andrew Wiley 2019 Irrevocable Trust Disclosed balance after: 3,241 F2 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.57 to $101.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.